Amylin Pharmaceuticals Inc - Current report filing (8-K)
April 21 2008 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13
or 15(d) of
the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported):
April 21, 2008
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
0-19700
|
|
33-0266089
|
(State or Other
Jurisdiction of
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
Incorporation)
|
|
|
|
|
9360 Towne Centre Drive
San Diego, California 92121
(Address of principal executive offices and zip code)
Registrants telephone number, including area
code:
(858)
552-2200
Check the appropriate box below if the Form 8-K is
intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General
Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CRF 240.13e-4(c))
Item
2.02. Results of Operations and
Financial Condition.
On April 21, 2008, Amylin
Pharmaceuticals, Inc. issued a press release announcing its financial
results for the quarter ended March 31, 2008. A copy of this press
release is attached as Exhibit 99.1 and is incorporated herein by
reference.
Item 9.01. Financial Statements
and Exhibits.
(d)
Exhibits.
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release
issued by Amylin on April 21, 2008
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AMYLIN
PHARMACEUTICALS, INC.
|
|
|
|
|
|
Dated: April 21,
2008
|
By:
|
|
|
|
Lloyd A. Rowland
|
|
|
Vice
President, Governance and Compliance,
|
|
|
and
Corporate Secretary
|
3
EXHIBIT
INDEX
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release
issued by Amylin on April 21, 2008.
|
4
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024